21 February 2013 
EMA/CHMP/108789/2013 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Privigen 
human normal immunoglobulin (ivig) 
On 21 February 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion  recommending  a  variation  to  the  terms  of  the  marketing  authorisation  for  the  medicinal 
product Privigen. The marketing authorisation holder for this medicinal product is CSL Behring GmbH. 
They  may  request  a  re-examination  of  the  CHMP  opinion,  provided  that  they  notify  the  European 
Medicines Agency in writing of their intention within 15 days of receipt of the opinion. 
The CHMP adopted a new indication as follows: 
Immunomodulation in adults, and children and adolescents (0-18 years) in: 
• 
Chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available 
of use of intravenous immunoglobulins in children with CIDP. 
Detailed  conditions  for  the  use  of  this  product  will  be  described  in  the  updated  summary  of  product 
characteristics  (SmPC),  which  will  be  published  in  the  revised  European  public  assessment  report 
(EPAR),  and  will  be  available  in  all  official  European  Union  languages  after  the  variation  to  the 
marketing authorisation has been granted by the European Commission. 
For information, the full indications for Privigen will be as follows2: 
Replacement therapy in adults, and children and adolescents (0-18 years) in: 
• 
• 
• 
Primary immunodeficiency (PID) syndromes with impaired antibody production (see section 4.4). 
Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic 
leukaemia, in whom prophylactic antibiotics have failed. 
Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma 
patients who have failed to respond to pneumococcal immunisation. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
2 The text in bold represents the new or the amended indication. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 7455 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
                                                
• 
• 
Hypogammaglobulinaemia  in  patients  after  allogeneic  haematopoietic  stem  cell  transplantation 
(HSCT). 
Congenital AIDS with recurrent bacterial infections. 
Immunomodulation in adults, and children and adolescents (0-18 years) in: 
• 
• 
• 
• 
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery 
to correct the platelet count. 
Guillain-Barré syndrome. 
Kawasaki disease. 
Chronic  inflammatory  demyelinating  polyneuropathy  (CIDP).  Only  limited  experience 
is available of use of intravenous immunoglobulins in children with CIDP. 
Privigen 
EMA/CHMP/108789/2013  
Page 2/2 
 
 
 
 
 
